TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Takotsubo Syndrome | NYU Langone Health
NYU Langone Heart cardiologists are experts at diagnosing and treating takotsubo syndrome, also known as broken heart syndrome.
Talking with Your Child About Medical Care | NYU Langone Health
We offer age-specific tips on how to talk with your child about medical care at Hassenfeld Children’s Hospital at NYU Langone.
TARGET-IBD: A longitudinal observational study of patients undergoing therapy for inflammatory bowel disease (IBD)
This is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2and above) undergoing IBD therapy designed to specifically address important clinicalquestions that remain incompletely answered from registration trials. In addition to thestudy database, a biospecimen repository will also be included so that translational studiesof viral resistance, genomics, and biomarkers of response may be performed. Also, theright to collect retrospective data on these IBD patients will be reserved
Targeted Drugs & Immunotherapy for Melanoma | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center may prescribe targeted drugs or immunotherapy for advanced melanoma.
Targeted Therapies for Liver Cancer & Liver Metastases | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center may recommend targeted drugs or radiation to treat liver cancer or liver metastases.
Targeted Therapy for Stomach Cancer | NYU Langone Health
NYU Langone doctors may prescribe targeted therapy, using drugs that block the growth and spread of cancer cells, to manage stomach cancer.
Targeting CD38 with Daratumumab in Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safety Trial
The purpose of this research study is to assess the safety of daratumumab (Darzalex®) and whether it may reduce levels of antiphospholipid antibodies, a blood protein in the immune system that mistakenly creates antibodies that attack tissues in the body, in patients with antiphospholipid syndrome (APS).
tDCS Program | NYU Langone Health
NYU Langone’s Transcranial Direct Current Stimulation Program offers at-home tDCS sessions through the NYU Langone Health app.
tDCS Program Doctors | NYU Langone Health
Find a doctor at the tDCS Program at NYU Langone.